Kiniksa Pharmaceuticals, Ltd.
NASDAQ: KNSA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sanj K. Patel
- Employees
- 315
- Headquarters
- Hamilton, United States
- IPO year
- 2018
- Market cap
- $4.1B
- Website
- https://www.kiniksa.com
Loading KNSA…
Loading profile data…Frequently asked questions about KNSA
What does Kiniksa Pharmaceuticals, Ltd. (KNSA) do?
Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. Its pipeline of potential treatments includes ARCALYST, an interleukin-1alpha and interleukin-1bet...
Where does KNSA trade?
Kiniksa Pharmaceuticals, Ltd. (KNSA) trades on the NASDAQ Global Select.
What sector is KNSA in?
Kiniksa Pharmaceuticals, Ltd. (KNSA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kiniksa Pharmaceuticals, Ltd.?
Sanj K. Patel is the chief executive officer of Kiniksa Pharmaceuticals, Ltd. (KNSA).
Where is Kiniksa Pharmaceuticals, Ltd. headquartered?
Kiniksa Pharmaceuticals, Ltd. is headquartered in United States.
Does KNSA pay a dividend?
Kiniksa Pharmaceuticals, Ltd. (KNSA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KNSA go public?
Kiniksa Pharmaceuticals, Ltd. (KNSA) completed its initial public offering in 2018.